

02 July 2015
EMA/33305/2015
Human Medicines Research and Development Support Division

Public summary of the evaluation of a proposed product-specific waiver

Hydromorphone (hydrochloride) / naloxone (hydrochloride) for treatment of pain and treatment of opioid-induced constipation

On 16 January 2015, the Paediatric Committee of the European Medicines Agency agreed a product-specific waiver* for hydromorphone (hydrochloride) / naloxone (hydrochloride) for the for treatment of pain and treatment of opioid-induced constipation (EMA-001699-PIP01-14).

What is hydromorphone (hydrochloride) / naloxone (hydrochloride), and how is it expected to work?

Hydromorphone (hydrochloride) is expected to relieve pain. Naloxone (hydrochloride) is expected to relieve constipation that can occur with hydromorphone (hydrochloride) treatment.

The combination of hydromorphone (hydrochloride) / naloxone (hydrochloride) is a medicine proposed for the substitution therapy for adult patients whose severe pain is adequately controlled with hydromorphone twice daily and whose opioid-induced constipation (OIC) is adequately controlled with naloxone both given as individual medicines. This combination is not currently authorised in the European Union.

What was the proposal from the applicant?

For children, the applicant proposed not to do any study in children (from birth to less than 18 years of age), because hydromorphone (hydrochloride) / naloxone (hydrochloride) is likely not to be safe. Therefore, the applicant requested an exemption (waiver*) from the obligation to study the medicine in any children, in the conditions treatment of pain and treatment of opioid-induced constipation.

Is there a need to treat children affected by pain and opioid induced constipation?

Taking into account the proposed indication in adults, the Paediatric Committee considered that there could be a need for the treatment of pain and treatment of opioid-induced constipation in the paediatric population since this condition occurs also in children.

What did the Paediatric Committee conclude on the potential use of this medicine in children?

The Committee agreed with the request of the applicant to be exempt from performing studies in children from birth to less than 18 years, because the Committee concluded that, due to lack of individual and flexible dosing of this combination of two medicines and since individual and separate dose adjustments of hydromorphone (hydrochloride) and naloxone (hydrochloride) are necessary to treat patients across all age groups, this medicine is likely to be unsafe for the treatment of pain and treatment of opioid-induced constipation in children.

What is the content of the Plan after evaluation?

The Paediatric Committee considered that studies are not necessary in children from birth to less than 18 years because this medicinal product is likely to be unsafe for the treatment of pain and treatment of opioid-induced constipation in children.

What happens next?

The applicant has now received the EMA Decision (P/0048/2015)* on this medicine. The Decision itself is necessary for the applicant to request in the future a marketing authorisation* for this medicine in adults.

***Definitions:**

Applicant	The pharmaceutical company or person proposing the Paediatric Investigation Plan or requesting the Product-Specific Waiver
Children	All children, from birth to the day of the 18 th birthday.
Paediatric investigation plan (PIP)	Set of studies and measures, usually including clinical studies in children, to evaluate the benefits and the risks of the use of a medicine in children, for a given disease or condition. A PIP may include “partial” waivers (for example, for younger children) and/or a deferral (see below).
Waiver	An exemption from conducting studies in children, for a given disease or condition. This can be granted for all children (product-specific waiver), or in specific subsets (partial waiver): for example, in boys or in children below a given age.
Deferral	The possibility to request marketing authorisation for the use of the medicine in adults, before completing one or more of the studies /measures included in a PIP. The Paediatric Committee may grant a deferral to avoid a delay in the availability of the medicine for adults.
Opinion	The result of the evaluation by the Paediatric Committee of the European Medicines Agency. The opinion may grant a product-specific waiver, or agree a PIP.
Decision	The legal act issued by the European Medicines Agency, which puts into effect the Opinion of the Paediatric Committee.
Pharmaceutical form	The physical aspect of the medicine (the form in which it is presented), for example: a tablet, capsule, powder, solution for injection, etc. A medicine can have more than one pharmaceutical form.
Placebo	A substance that has no therapeutic effect, used as a control in testing new drugs.
Active control	A medicine with therapeutic effect, used as a control in testing new drugs.
Historical control	A group of patients with the same disease, treated in the past and used in a comparison with the patients treated with the new drug.
Route of administration	How a medicine is given to the patient. For example: for oral use, for intramuscular use, for intravenous use, etc. The same medicine, or the same pharmaceutical form, may be given through more than one route of administration.
Patent	A form of protection of intellectual property rights. If a medicinal product is protected by a patent, the patent holder has the sole right to make, use, and sell the product, for a limited period. In certain circumstances, a patent for a medicinal product may be extended for a variable period by a Supplementary Protection Certificate.
Marketing Authorisation	When a Marketing Authorisation is granted, the pharmaceutical company may start selling the medicine in the relevant country (in the whole European Union, if the procedure was a centralised one).